277 related articles for article (PubMed ID: 32836074)
1. Anti-EGFR therapies in nasopharyngeal carcinoma.
Chen X; Liang R; Zhu X
Biomed Pharmacother; 2020 Nov; 131():110649. PubMed ID: 32836074
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFR in nasopharyngeal carcinoma.
Kyrodimos E; Chrysovergis A; Mastronikolis N; Tsiambas E; Ragos V; Roukas D; Fotiades P; Papanikolaou V
J BUON; 2021; 26(3):759-761. PubMed ID: 34268932
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a new dual-targeting fully human antibody with potent antitumor activity against nasopharyngeal carcinoma.
Xie S; Zhu X; Li Y; Li L; Si Y; Yang N
Biol Chem; 2015 Aug; 396(8):917-21. PubMed ID: 25429597
[TBL] [Abstract][Full Text] [Related]
4. Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma.
Liang R; Yang L; Zhu X
Cancer Control; 2021; 28():1073274821989301. PubMed ID: 33504193
[TBL] [Abstract][Full Text] [Related]
5. Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study.
Sun XS; Liang YJ; Li XY; Liu SL; Chen QY; Tang LQ; Mai HQ
Drug Des Devel Ther; 2019; 13():3207-3216. PubMed ID: 31686783
[TBL] [Abstract][Full Text] [Related]
6. Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells.
Lui VW; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Tsang CM; Lei KI; Chan AT; Mok TS
Invest New Drugs; 2011 Dec; 29(6):1241-52. PubMed ID: 20571878
[TBL] [Abstract][Full Text] [Related]
7. Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.
Hu WJ; Liu J; Zhong LK; Wang J
Biomed Pharmacother; 2018 Jun; 102():681-688. PubMed ID: 29604587
[TBL] [Abstract][Full Text] [Related]
8. Specific targeting of nasopharyngeal carcinoma cell line CNE1 by C225-conjugated ultrasmall superparamagnetic iron oxide particles with magnetic resonance imaging.
Liu D; Chen C; Hu G; Mei Q; Qiu H; Long G; Hu G
Acta Biochim Biophys Sin (Shanghai); 2011 Apr; 43(4):301-6. PubMed ID: 21345916
[TBL] [Abstract][Full Text] [Related]
9. Targeted blocking of EGFR and GLUT1 by compound H reveals a new strategy for treatment of triple-negative breast cancer and nasopharyngeal carcinoma.
Wang C; Li Z; Zhai H; Shen X; Li F; Zhang Q; Li D; Hou H
Eur J Pharm Sci; 2024 Jul; 198():106789. PubMed ID: 38710335
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study comparing anti-EGFR monoclonal antibody plus cisplatin-based chemoradiotherapy versus chemoradiotherapy alone for stage II-IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression.
Mao L; Tan J; Wang F; Luo Y; Liu W; Zeng F; Yu B; Huang H; Lu J; Peng X; Liu X
Clin Otolaryngol; 2019 Jul; 44(4):572-580. PubMed ID: 30972891
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells.
Sung FL; Poon TC; Hui EP; Ma BB; Liong E; To KF; Huang DP; Chan AT
In Vivo; 2005; 19(1):237-45. PubMed ID: 15796181
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological background of EGFR targeting.
Castillo L; Etienne-Grimaldi MC; Fischel JL; Formento P; Magné N; Milano G
Ann Oncol; 2004 Jul; 15(7):1007-12. PubMed ID: 15205192
[TBL] [Abstract][Full Text] [Related]
13. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
14. Sodium butyrate induces autophagic apoptosis of nasopharyngeal carcinoma cells by inhibiting AKT/mTOR signaling.
Huang W; Zeng C; Liu J; Yuan L; Liu W; Wang L; Zhu H; Xu Y; Luo Y; Xie D; Jiang X; Ren C
Biochem Biophys Res Commun; 2019 Jun; 514(1):64-70. PubMed ID: 31023529
[TBL] [Abstract][Full Text] [Related]
15. VPS33B interacts with NESG1 to modulate EGFR/PI3K/AKT/c-Myc/P53/miR-133a-3p signaling and induce 5-fluorouracil sensitivity in nasopharyngeal carcinoma.
Liang Z; Liu Z; Cheng C; Wang H; Deng X; Liu J; Liu C; Li Y; Fang W
Cell Death Dis; 2019 Apr; 10(4):305. PubMed ID: 30944308
[TBL] [Abstract][Full Text] [Related]
16. Foxq1 promotes metastasis of nasopharyngeal carcinoma by inducing vasculogenic mimicry via the EGFR signaling pathway.
Luo Y; Wang J; Wang F; Liu X; Lu J; Yu X; Ma X; Peng X; Li X
Cell Death Dis; 2021 Apr; 12(5):411. PubMed ID: 33875643
[TBL] [Abstract][Full Text] [Related]
17. EGFR-PKM2 signaling promotes the metastatic potential of nasopharyngeal carcinoma through induction of FOSL1 and ANTXR2.
Chen S; Youhong T; Tan Y; He Y; Ban Y; Cai J; Li X; Xiong W; Zeng Z; Li G; Yi M; Liu W; Xiang B
Carcinogenesis; 2020 Jul; 41(6):723-733. PubMed ID: 31665243
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors.
Sun Y; Fry DW; Vincent P; Nelson JM; Elliott W; Leopold WR
Anticancer Res; 1999; 19(2A):919-24. PubMed ID: 10368634
[TBL] [Abstract][Full Text] [Related]
19. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY
Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
